FDA pilot offers generative AI medical devices a path to patients before authorization

AI justification

Pilot lowers safety safeguards, posing net risk. | While the pilot could speed delivery of AI health innovations, it bypasses established safety reviews, raising significant patient‑risk concerns. The potential harms to health and the erosion of regulatory safeguards outweigh the anticipated benefits, leading to a net negative ethical assessment.